Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.49 |
| ▸ | INSR | P06213 | 4/20 | 0.49 |
| ▸ | IGF1R | P08069 | 3/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | FES | P07332 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22985931 | 0.91 | ALK (0.46) | EGFRALKINSRIGF1RERBB2 | |
| SCHEMBL22985882 | 0.86 | EGFR (0.48) | EGFRALKFES | |
| SCHEMBL18018913 | 0.85 | EGFR (0.51) | EGFRALKINSRIGF1RERBB2 | |
| SCHEMBL18018866 | 0.79 | EGFR (0.49) | EGFRALKINSRIGF1RERBB2 | |
| SCHEMBL18018892 | 0.77 | TTK (0.50) | EGFRALKINSRIGF1RERBB2 | |
| SCHEMBL18018861 | 0.76 | TTK (0.48) | EGFRALKINSRIGF1RTTK | |
| SCHEMBL18018904 | 0.74 | LRRK2 (0.51) | EGFRALKINSRIGF1RTTK | |
| SCHEMBL18018891 | 0.74 | TTK (0.48) | EGFRALKINSRIGF1RERBB2 | |
| SCHEMBL18018888 | 0.73 | ALK (0.49) | EGFRALKINSRIGF1RERBB2 | |
| SCHEMBL18018863 | 0.73 | ALK (0.49) | EGFRALKINSRIGF1RTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |